Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
S Hetherington, AR Hughes, M Mosteller, D Shortino… - The Lancet, 2002 - thelancet.com
S Hetherington, AR Hughes, M Mosteller, D Shortino, KL Baker, W Spreen, E Lai, K Davies…
The Lancet, 2002•thelancet.comHypersensitivity to abacavir affects about 4% of patients who receive the drug for HIV-1
infection. We did a retrospective, case-control study to identify multiple markers in the vicinity
of HLA-B associated with hypersensitivity reactions. HLA-B57 was present in 39 (46%) of 84
patients versus four (4%) of 113 controls (p< 0· 0001). However, because of low numbers of
women and other ethnic groups enrolled, these findings relate largely to white men. The
lower sensitivity of HLA-B57 for predicting hypersensitivity to abacavir identified in this study …
infection. We did a retrospective, case-control study to identify multiple markers in the vicinity
of HLA-B associated with hypersensitivity reactions. HLA-B57 was present in 39 (46%) of 84
patients versus four (4%) of 113 controls (p< 0· 0001). However, because of low numbers of
women and other ethnic groups enrolled, these findings relate largely to white men. The
lower sensitivity of HLA-B57 for predicting hypersensitivity to abacavir identified in this study …
Summary
Hypersensitivity to abacavir affects about 4% of patients who receive the drug for HIV-1 infection. We did a retrospective, case-control study to identify multiple markers in the vicinity of HLA-B associated with hypersensitivity reactions. HLA-B57 was present in 39 (46%) of 84 patients versus four (4%) of 113 controls (p< 0·0001). However, because of low numbers of women and other ethnic groups enrolled, these findings relate largely to white men. The lower sensitivity of HLA-B57 for predicting hypersensitivity to abacavir identified in this study compared with a previous report highlights that predictive values for markers will vary across populations. Clinical monitoring and management of hypersensitivity reactions among patients receiving abacavir must remain unchanged.
thelancet.com